Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.

Ezogabine has gained approval as an adjunctive treatment for focal-onset seizures in patients aged 18 and older. Its efficacy in enhancing seizure control makes it a valuable addition to the armamentarium of antiepileptic drugs. However, its use was discontinued in 2017 in the US due to concerns about its safety.

The drug's oral administration offers convenience for patients and healthcare providers alike. Furthermore, it boasts rapid absorption following administration, ensuring a swift onset of action.

Ezogabine undergoes metabolism through processes such as glucuronidation and acetylation. This intricate metabolic pathway contributes to its pharmacokinetic profile. The drug exhibits a half-life spanning 7 to 11 hours, indicating its suitability for maintaining therapeutic levels in the bloodstream.

Both ezogabine and its metabolites are primarily excreted through the urine, offering a predictable route of elimination.

As with many medications, ezogabine is associated with various adverse effects, although not all patients may experience them. Common side effects include dizziness, drowsiness, fatigue, confusion, and blurred vision. These effects may impact a patient's daily activities and should be monitored closely.

In addition to the common adverse effects, ezogabine has been associated with other potential side effects, such as vertigo, diplopia, and memory impairment. Notably, neuropsychiatric symptoms, including suicidal thoughts and behavior, have been reported in some individuals. The U.S. Food and Drug Administration (FDA) has issued warnings about the risks of these serious adverse effects, some of which may have long-lasting consequences.

章から 17:

article

Now Playing

17.8 : Antiepileptic Drugs: Potassium Channel Activators

Pharmacotherapy of the Epilepsies

42 閲覧数

article

17.1 : 下肢の動脈

Pharmacotherapy of the Epilepsies

102 閲覧数

article

17.2 : 発作:分類

Pharmacotherapy of the Epilepsies

164 閲覧数

article

17.3 : 抗てんかん薬:ナトリウムチャネル遮断薬

Pharmacotherapy of the Epilepsies

59 閲覧数

article

17.4 : 抗てんかん薬:GABA作動性経路増強剤

Pharmacotherapy of the Epilepsies

157 閲覧数

article

17.5 : 抗てんかん薬:カルシウムチャネル遮断薬

Pharmacotherapy of the Epilepsies

70 閲覧数

article

17.6 : 抗てんかん薬:グルタミン酸拮抗薬。

Pharmacotherapy of the Epilepsies

147 閲覧数

article

17.7 : 抗てんかん薬:SV2Aタンパク質が媒介する神経伝達物質放出の調節因子

Pharmacotherapy of the Epilepsies

99 閲覧数

JoVE Logo

個人情報保護方針

利用規約

一般データ保護規則

研究

教育

JoVEについて

Copyright © 2023 MyJoVE Corporation. All rights reserved